Assessment of the safety and efficacy of fondaparinux as an anticoagulant in haemofiltraion in patients with acute renal failure
Recruiting
- Conditions
- Patients requiring haemofiltration for acute renal failure.Renal and Urogenital - Other renal and urogenital disorders
- Registration Number
- ACTRN12605000401651
- Lead Sponsor
- Intensive Care Unit, RMH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
The study will be conducted in the Intensive Care Unit at The Royal Melbourne Hospital and will aim to include patients who fulfill the following criteria: 1.Adult patients admitted to the ICU with an expected stay of more than 48h. 2.Patients who require continuous renal replacement therapy. 3.Patients who consent or if the patient is incompetent, the next-of-kin who consent, to inclusion in the study.
Exclusion Criteria
1.Patients who are pregnant. 2.Patients with a contra-indication to anticoagulation for pre-existing bleeding diathesis. 3.Patients or next-to-kin who do not consent to study inclusion.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The study will evaluate the duration of filter patency using fondaparinux as an anticoagulant in haemofiltration and compare this to current standard haemofilter anticoagulation with enoxaparin.[]
- Secondary Outcome Measures
Name Time Method To assess the incidence of complications, primarily bleeding, with fondaparinux compared to enoxaparin in this setting.[]